Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients

  • Parody-Rua, Elizabeth
  • Bustamante, Alejandro
  • Montaner, Joan
  • Rubio-Valera, María
  • Serrano, David
  • Pérez-Sánchez, Soledad
  • Sánchez-Viñas, Alba
  • Guevara-Cuellar, César
  • Serrano-Blanco, Antoni
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., [Objectives] Stroke treatment with intravenous tissue-type plasminogen activator (tPA) is effective and efficient, but as its benefits are highly time dependent, it is essential to treat the patient promptly after symptom onset. This study evaluates the cost-effectiveness of a blood biomarker test to differentiate ischemic and hemorrhagic stroke to guide pre-hospital treatment with tPA in patients with suspected stroke, compared with standard hospital management. The standard care for patients suffering stroke consists mainly in diagnosis, treatment, hospitalization and monitoring., [Methods] A Markov model was built with four health states according to the modified Rankin scale, in adult patients with suspected moderate to severe stroke (NIHSS 4-22) within 4.5 hours after symptom onset. A Spanish Health System perspective was used. The time horizon was 15 years. Quality-adjusted life-years (QALYs) and life-years gained (LYGs) were used as a measure of effectiveness. Short- and long-term direct health costs were included. Costs were expressed in Euros (2022). A discount rate of 3% was used. Probabilistic sensitivity analysis and several one-way sensitivity analyses were conducted., [Results] The use of a blood-test biomarker compared with standard care was associated with more QALYs (4.87 vs. 4.77), more LYGs (7.18 vs. 7.07), and greater costs (12,807€ vs. 12,713€). The ICER was 881€/QALY. Probabilistic sensitivity analysis showed that the biomarker test was cost-effective in 82% of iterations using a threshold of 24,000€/QALY., [Conclusions] The use of a blood biomarker test to guide pre-hospital thrombolysis is cost-effective compared with standard hospital care in patients with ischemic stroke., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The present study is part of the Instituto de Salud Carlos III (ISCIII) grant, file number PMP15/00022, and Biomarkers for Initiating Onsite and Faster Ambulance Stroke Therapies (BIOFAST) DTS19/00135. We thank the Research Network on Preventative Activities and Health Promotion (redIAPP) (RD16/0007/0012), the European Regional Development Fund, and the CIBERESP (Centro de Investigación Biomedica en Red de Epidemiología y Salud Pública, CB16/02/00322), for their support in study development. Dr. A. Serrano-Blanco has a personal grant from the PERIS program (SLT006/17/68), Generalitat de Catalunya (Spain), to partially dedicate his time to research during the study period. Dr. Rubio-Valera has a “Miguel Servet” research contract from ISCIII, Ministry of Economy and Competitiveness (Spain) (CP19/00029)., Peer reviewed